Physician profile
Donevan Westerveld
NPI 1588027239
$7,473.98
in general payments reported to CMS, 2019-2025
31 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $906 · 2022: $664 · 2023: $1,941 · 2024: $1,669 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,527 · Travel and Lodging: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,526.61 |
| Travel and Lodging | $377.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.06 | 2022-2025 | Rinvoq, Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.09 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $544.82 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Medtronic, INC. | $544.70 | 2022-2025 | Interstim |
| Intra-Sana Laboratories | $500.00 | 2021 | |
| Qol Medical, LLC | $478.44 | 2023-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $421.68 | 2021-2022 | |
| Lilly USA, LLC | $325.25 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $296.96 | 2023-2025 | Dupixent |
| Cook Medical LLC | $264.93 | 2023 | Echotip |
| Pfizer INC. | $263.23 | 2024-2025 | |
| Mauna Kea Technologies, INC. | $260.16 | 2023 | |
| Axonics, INC. | $258.28 | 2023 | Axonics |
| Apollo Endosurgery US INC | $232.18 | 2021-2023 | Orbera Intragastric Balloon System |
| Gilead Sciences, INC. | $227.04 | 2023-2025 | Epclusa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $218.23 | 2023-2025 | |
| Janssen Biotech, INC. | $215.34 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $160.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $153.20 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $142.04 | 2022-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $128.80 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $107.57 | 2023-2024 | Dificid, Zerbaxa, Zinplava |
| Ardelyx, INC. | $78.56 | 2024-2025 | Ibsrela |
| Celgene Corporation | $68.39 | 2024 | Zeposia |
| Braintree Laboratories, INC. | $65.54 | 2023-2025 | Suflave |
| Alnylam Pharmaceuticals INC. | $53.13 | 2024 | Givlaari |
| Phathom Pharmaceuticals, INC. | $47.52 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $31.27 | 2024 | Iqirvo |
| Vivus LLC | $18.29 | 2024 | Qsymia |
| Ironwood Pharmaceuticals, INC | $13.84 | 2024 | |
| Amgen INC. | $13.76 | 2025 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donevan Westerveld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.